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Abstract 
 
 Background/Objective: Schizophrenia is one of the most disabling 
psychiatric disorders. Its etiology is still poorly understood and one of the strongest 
theories for it is the Neurodevelopmental Hypothesis. As genetic and environmental 
factors affect the risk for Schizophrenia, one of the less studied is Advanced Paternal 
Age. Described in earlier studies as a risk factor for Schizophrenia, we decided to 
describe the paternal age in a group of Portuguese patients. 
 Material and Methods: We included the patients admitted between 2009 and 
2013 with the diagnosis of Schizophrenia/Schizoaffective Disorder (ICD-10, WHO, 
1992). Age, sex, diagnosis, Paternal Age at Birth, Maternal Age at Birth and Birth 
Rank were collected from the admission registries.  
 Results: 241 patients were enrolled in this study, from which 85 had the data 
of the Paternal Age at Birth. The mean Paternal Age at Birth was 30.06 ± 6.79 years 
with a range of 15-52years, a median of 30.00 and a mood of 28. After categorizing 
the Paternal Age at Birth in 5 groups, the 25-29 years was dominant with 28 (32.9%) 
patients, followed by the 30-34 and 35-39 groups. In the Birth Rank, 126 patients had 
data; the mean was 2.18 ± 1.53. After categorizing, 1st was the leading group (56 
cases (44.4%)), followed by the ≥3rd group.  
 Discussion/Conclusions: The results achieved were comparable and 
similar to earlier studies, with a tendency for Advancing Paternal Age. Although 
limited by the missing data and the lack of comparison group, this study opens 
perspectives for further increasing and search for more consistent results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
Introduction 
 
Schizophrenia is one of the most severe and devastating psychiatric 
disorders that are known, since it affects the essence of the person’s identity – the 
most complex functions that the brain mediates. It is also a challenging pathology, 
since its manifestations are so diverse, as to include positive, negative, cognitive, 
affective and motor symptoms. Also, these clinical manifestations can be very 
variable, not following a pattern or a linear evolution.  
Positive symptoms are the one’s that make the patient loose contact with the 
reality, and they include hallucinations, delusions and thought disorders. 
Hallucinations can be visual, auditory (the most common type), olfactory, tactile, 
gustatory or even multisensory, and they can be playing many roles, most frequently 
hearing two people stating comments about the patient or a voice giving orders. In 
addition, they can be continuous or come and go, severe or mild. Delusions can be 
defined as false beliefs that are not part of the person’s culture and are 
unquestionable for the patient. It’s content can be widely miscellaneous, from 
believing that neighbors are controlling him with the use of magnetic waves, to 
thinking that they are someone else like an historical personality, among many 
others. Thought disorders are disabled ways of grouping the ideas. Schizophrenia 
patients can have difficulty on creating a logical organization with the thoughts, can 
have pauses when speaking because of blocking of thoughts, or can create new 
words. 
Negative symptoms are more related to disturbances in the emotions and 
behaviors, and can be misdiagnosed as depression or other conditions. They can 
disrupt the patient’s affection, pleasure, interaction and ability to plan activities. The 
capacity for doing the everyday tasks is lost, like the hygiene tasks. 
Cognitive symptoms can be delicate and, like the negative symptoms, can be 
hardly detectable. They can affect patient’s attention, memory or even the executive 
functioning, leading to great emotional stress and inability to have a normal life. 
Motor symptoms can be described as strange body movements that can be 
wide-ranging, from catatonia, repetition of certain movements for undefined periods 
of time to dyskinesia and parkinsonism(1). 
Epidemiological studies indicate that almost 1% of the population is affected 
by this condition during his life(2), with an estimated lifetime prevalence for 
Schizophrenia of 0.87% and for Schizoaffective Disorder of 0.32%(3). The incidence 
of this pathology is around 0.20/1000 per year, with a peak in de 15-24 years in both 
females and males, having the women another peak around the 55-64 years and the 
men a higher lifetime risk(4).  
Schizophrenia can be defined as a heterogeneous disease and the etiology is 
still little understood. There are lots of theories trying to link the genetic and 
environmental factors and explain the etiology of this disease(5). 
One of the strongest theories proposed to explain this doubts is the 
Neurodevelopmental Hypothesis, supported by epidemiological, genetic and 
neuropathological features that suggest its importance for the development of this 
disorder. It has been a long time since the first studies started describing 
Schizophrenia as one of the neurodevelopmental disorders(6). Even Kraepelin in 
1887 and Bleuler in 1911 noted abnormal neurological and behavioral signs in 
childhood histories of adults suffering from Schizophrenia. Early studies described 
Neurodevelopmental Hypothesis as a brain defect in the early development that 
predisposes to a specific arrangement of brain malfunction in the adult life, regarding 
the neuron migration and synapsis, from where Schizophrenia develops. So, authors 
expected that the abnormalities were silenced during the early childhood and during 
this latency period the cerebral function showed itself normal or near normal. At the 
disease onset the brain function would then express several malfunction(7). Recent 
studies added that the brain development progresses throughout the life, as it 
	  
includes the neuronal and synaptic formation and migration, but also myelination, 
neuronal pruning and also neuronal plasticity(8).  So doubts appeared from how 
could the cerebral damage be disguised until the age of onset of Schizophrenia? 
Neurodevelopment can explain this, showing that the brain damage can occur not 
only in the early stages of life, but can be seen as a continuous line that can occur 
during all life, before and after the onset of the disorder. (8)    
Genetic studies showed Schizophrenia’s heritability could go up to 80%(9). 
Moreover, anatomical and imaging studies showed minor physical anomalies, like 
the increase of the cerebrospinal liquid, reduction of the lobe and gray matter 
volumes in certain areas of the brain and also an increase in the ventricles(10). 
Investigators have been increasingly demonstrating that the integrity of the synaptic 
system, the transduction pathways and the glumate-related receptors has a pivotal 
role in the brain development, synapsis formation and plasticity. Besides that, genes 
like schizophrenia-1, neuroregulin-1, dysbindin-1 and AKT-1, that represent most of 
the genes associated with Schizophrenia, have also a function on the 
neurodevelopment, neurotransmission and neuroplasticity(11). 
So, some of the above-mentioned features denoted in Schizophrenia can be 
assigned to abnormal expression of these genes associated with neurodevelopment. 
Also, The interaction of genetic-environmental factors has been exhibited in 
Schizophrenia(12). It is known that cannabis abuse, stress periods during 
neurodevelopment, infections and obstetric complications (during pregnancy and at 
birth) can act as environmental factors increasing the risk for development of 
Schizophrenia(13). So, the genes involved can be influenced or triggered by the 
environmental factors to enhance the risk for Schizophrenia.  
Several have been the stated risk factors for Schizophrenia, and one of the 
least studied is the Paternal Age. Advanced paternal age has been linked to 
Schizophrenia and confirmed as a risk factor in several studies (14-20), as first 
reports date since in the 1950s and 1960s. Malaspina et al, in 2001, investigated this 
effect in a population-based cohort in Jerusalem. Their results displayed a more than 
4-fold difference in the risk for Schizophrenia between the oldest Paternal Age 
categories and the youngest ones. More than a quarter of the Schizophrenia cases 
were attributable to Paternal Age effect(14). In 2002, Brown and co-workers used the 
same cohort study configuration in the USA, showing similar results and adding that 
the risk unfolded by the Advanced Paternal Age was different and higher in 
Schizophrenia when compared to other psychoses(15). A case-control study in Iran, 
repeated the positive relationship between Paternal Age and risk for Schizophrenia, 
but added the effect of the Birth Rank, stating that Birth Rank equal or higher than 3, 
along with the Advanced Paternal Age, were linked to the risk for Schizophrenia(18). 
Some studies also contradicted this linkage(21).  
Other investigators studied the relationship of the Paternal Age with Sporadic 
Schizophrenia vs. Familiar Schizophrenia, showing significantly older fathers in the 
Sporadic cases in comparison with the Familiar ones. This can accomplish that the 
Advanced Paternal Age is not a consequence of delayed childbearing from fathers 
who carry a genetic risk for Schizophrenia and supports the hypothesis of de novo 
mutations, likely in the paternal germ lines, contribute to the risk for Sporadic 
Schizophrenia. The results showed differences around 4.7 years between the 
sporadic and the familial ones and linking approximately 27% of the sporadic cases 
to Paternal Age(22).  
 Considering the results from the studies displayed above, Rosenfield et al set 
the hypothesis that may exist a Paternal-Age Related Schizophrenia (PARS), 
involving a different etiopathology and specific characteristics from the other 
Schizophrenia cases. This group was defined as Sporadic cases with Paternal Age 
≥35 years. PARS cases revealed more pronounced symptoms in the medication-free 
periods and better response to antipsychotic medication(23). Later, in 2011, Lee et al 
	  
continued to study this hypothesis, with results enhancing this evidence and 
suggesting discrepancies in the verbal performance and age of onset(24).	  
 Some studies also tried to remove confounding factors like Maternal Age and 
family history to seek this relationship (15, 20), as Maternal Age has been associated 
with an increased risk in some of the primordial studies(15).  
So, we are facing a great challenge, is Paternal Age a risk factor or part of a 
source of a different etiopathology for Schizophrenia?  
Early research acknowledged that the major source of new mutations in 
humans is from Advanced Paternal Age (25), due to an increased rate of mitotic cell 
division in sperm cells comparing to the oocytes, and an higher risk of genetic 
errors(26). A linkage between Advanced Paternal Age and chromosomal 
abnormalities, aneuploidies and other damage on the DNA in both human and mice 
sperm has been descripted(27). It is important to mention that the Paternal Age at 
Birth is increasing nowadays in the Western Civilizations along with the Maternal 
Age, probably due to economic, education and marriage changing patterns(28). With 
these evidences, we could be looking to a good source of diseases like the so called 
“paternal age” diseases(29). Can we insert Schizophrenia in this group of diseases? 
The objective of this study is to describe the Age of Parents at Birth and the 
birth rank of a sample of patients suffering from Schizophrenia/Schizoaffective 
Disorder in Portuguese Population, a typically Western Europe country where there 
is still no registry of having a study of this topic. So this is a pioneer study, in which 
we question, if Advanced Paternal Age is a stated risk factor for Schizophrenia, 
whether we could reach results that would describe an effect of Advanced Paternal 
Age and higher Birth Rank on the risk for Schizophrenia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
Methods 
 
 
This study was made from the registries of admissions on the Psychiatrics 
and Mental Health Department of Centro Hospitalar São João, Oporto, Portugal. This 
department contains the registries on these admissions since 1978. We used the 
registries dated from 1 of January of 2009 until 31 of December of 2013 and 
screened those that had the admission diagnosis of Schizophrenia and 
Schizoaffective Disorder. All the other diagnosis were excluded. The classification 
used in the clinical records is the International Classification of Disease (ICD), 10th 
version, by World Health Organization, since 1992(30).  
A total of 241 patients were initially included by their diagnosis and we had 
access to all of their admission registries. The data collected was age at that time of 
admission and birthdate, diagnosis credited by the psychiatrist, data of the 
registration, age of mother, Age of father and Birth Rank. Using the mother/father 
age and the age of the patient at the registry we calculated the Age of Mother/Father 
at the Birth of the patient, having relied on the registries of the admissions made by 
the responsible psychiatrics. For the statistic data of the age at birth we excluded 
those who had no data of age of mother and/or father. So, there were a total of 132 
(54,8%) of patients that were excluded from statistics regarding data of Age of 
Mother at Birth and 156 (64.7%) excluded from the statistics staring the Age of 
Father at Birth. So, there were 109 (45.2%) and 85 (35.3%), respectively, included in 
this data statistics.  
Gender, diagnosis were defined as categorical variables, with age at the 
admission, Mother Age at Birth, Father Age at Birth, Birth Rank defined as 
continuous and ordinal variables. All variables were characterized with descriptive 
statistics by calculating mean, standard deviation, range, median and mood. 
Paternal Age at Birth and Birth Rank were then categorized, respectively into 
5 (<25, 25-29, 30-34, 35-39 and ≥40 years) and 3 groups (1st child, 2nd child and ≥3rd 
child). The same descriptive statistics was applied to these categorical variables. 
Tables and graphics were created with the data from the statistic analysis.  
The statistic analysis was performed with the use of IBM® SPSS® Statistics 
21. 
 The Ethics Committee of Centro Hospitalar São João approved the execution 
of this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
Results 
 
 
 In this study 241 patients were admitted. The majority of them were male 
(68.5%) and the mean age in the admission was 41.91±12.51 years with a range of 
60, from a minimum of 19 years to a maximum of 81 years old for all patients. The 
mean age in female patients was 44.51±14.13 years, higher then in male patients, 
where it was 40.71±14.13 years. Considering the diagnosis, 46 (19.1%) had 
Schizoaffective Disorder and 195 (80.9%) had Schizophrenia diagnosis. Considering 
the subtype of Schizophrenia, 156 (80.0%) had Paranoid subtype, 13 (6.7%) had 
Hebephrenic subtype, 17 (8.7%) had Residual subtype, 1 (0.5%) had Simple subtype 
and 8 (4.1%) were diagnosed with Schizophreniform psychosis. This data is 
summarized in Table 1. 
 Concerning the Parents Age at Birth, we started by considering both Paternal 
and Maternal Age at Birth as continuous variables. Overall, there were 117 cases 
with the data from the Paternal Age at Birth plus Maternal Age at Birth missing. 
Furthermore, in the Maternal Age at Birth there were 132 cases of missing records 
(54.8%) and in the Paternal Age at Birth 156 cases (64.7%) (Table 2). The mean 
Maternal Age at Birth was 28.01 ± 7.28 years, extending from 14 to 54, with a mood 
of 24 and a median of 27.00, while the mean Paternal Age at Birth of the patients 
was 30.06 ± 6.79 with a minimum of 15 and a maximum of 52, a median of 30.00 
and a mood of 28 (Table 3). So we could conclude that Father’s Age at Birth was, on 
average, higher. 
 The Paternal Age at Birth of the patient was then categorized into 5 age 
groups: <25, 25-29, 30-34, 35-39 and ≥40 years. Focusing on this, from a total of 85 
patients with data available, the group that had the highest number of patients was 
the 25-29 age group with 28 patients (32.9%) followed by the 30-34 and 35-39 with, 
respectively, 19 (22.4%) and 17 (20.0%) patients. The group with the lowest patients 
was the ≥40 age group (Table 4). Figure 1 summarizes this data.  
Considering the Birth Rank, there were 115 (47.7%) cases missing the data 
from the order of their birth (Table 2). The mean rank was 2.18 ± 1.53 with the range 
from 1 to 10, median of 2.00 and mood of 1 (Table 3). After categorizing this variable 
into 3 groups as 1st child, 2nd child and ≥3rd child, the results were, correspondingly, 
56 (44.4%) 32 (25.4%) and 38 (30.2%) patients, not showing a big difference 
between the 3 groups (Table 4 and Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
Discussion 
 
  The main goal for this study was to describe the Paternal Age at Birth of 
patients admitted with the diagnosis of Schizophrenia between 2009 and 2013 in the 
Psychiatric Department of Centro Hospitalar São João. We aimed to evaluate the 
possibility of the Advanced Paternal Age, a major source of de novo mutations(25), 
in accordance with the Neurodevelopmental Hypothesis, could suggest an effect of 
Paternal Age at Birth in the risk for Schizophrenia in the offspring.  
The results achieved show us, first of all, higher number of male patients and 
a dominant diagnosis of Paranoid Schizophrenia, in similarity with the worldwide 
known facts from Schizophrenia(31). 
As far as Paternal Age is concerned, our study, as descriptive, can only have 
its results compared to the cases groups from other studies. 
Comparing the results achieved with other studies, our mean Age of Father at 
Birth was very similar to the one described by Naserbakth et al, in the case-control 
study in Iranian population, which also added that there was a growing risk with the 
increasing of Paternal Age at Birth(18). It can be concluded that this study had a 
higher number of cases in the groups above the reference age group. Our study 
shows a similar distribution of the cases by the analysis of Figure 1, in agreement 
with the previous cited study. Several other studies also confirmed this risk increase, 
by having higher number of cases in the older groups and emphasizing the effect of 
Paternal Age at Birth in this disease(16, 19). 
Considering the Birth Rank, higher Birth Rank is likely to determine older 
father in comparison with first-born children. The Iranian population-based study 
sustained an increased risk with the higher Birth Rank(18). Our result showed a 
predominance of first-born children but the third or above born child category was the 
second with most cases, showing some tendency for higher Birth Rank (Figure 2), 
although this factor needed more cases to be viable in the conclusions advanced 
from it. 
Advanced Paternal Age, not only is a major source of de novo mutations(25), 
as cited before in this study, but also is associated with elevated incidence of 
environmental exposures that may disturb the spermatozoid development. The new 
developments in the Neurodevelopmental Hypothesis suggest there has to be not 
only genetic predisposition and damage but also environmental-induced changes to 
DNA that can affect the brain development. (8, 12, 13, 25) Advanced Paternal Age 
was identified as the major source of de novo mutations and its accumulation would 
occur in an exponential way, rather than a linear one(25). As Malaspina et al 
proposed, the de novo mutations coming from the paternal germ cells could be a 
source of risk for Schizophrenia(22). These de novo mutations has been linked to 
several other diseases, like prostate cancer, Apert syndrome and 
craniosynostosis(32-34). 
Furthermore, Zammit et al showed that the Paternal Age effect for 
Schizophrenia was greater comparing to other psychosis, strengthening the 
hypothesis that Advanced Paternal Age is a risk factor for Schizophrenia(35). 
 This study was harshly limited by the missing data and the lack of a control-
comparing group, as the National Institute of Statistics doesn’t gather data from Age 
of Fathers at the Birth. This has restricted the results, the statistic analysis but also 
doesn’t allow us to conclude that the results achieved represent a subgroup of ill 
people or just represent the distribution of the national population. Anyway, the 
objective of the study was achieved, as the results described can be linked to the 
results from the cases of the earlier studies and there was a similarity between them 
and the corresponding cases in the other studies. This study can be further extended 
in the number of cases that can be amplified by increasing the year range. With this 
we can give more viable results and boost the relation between Paternal Age and the 
risk for Schizophrenia. 
	  
 
Conclusion 
 
In this study we could corroborate and replicate the results from the previous 
studies that searched the effect of Advanced Paternal Age in the risk for 
Schizophrenia. Although clearly limited by the high number of missing cases and the 
lack of a comparison group, this study is likely to be increased in order to achieve 
more consistent results and have a better overview of the effect of Advanced 
Paternal Age in the risk for Schizophrenia.  
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Tables and Figures 
 
 
Table 1 Patients overall characteristics 
Variables n = 241 
  Age (years) – mean ± SD 41.91 ± 12.51 
     Male 40.71 ± 11.44 
     Female 44.51 ± 13.31 
  Gender – n (%)  
     Male 165 (68.5%) 
     Female 76 (31.5%) 
  Diagnosis – n (%)  
     Schizoaffective Disorder 46 (19.1%) 
     Schizophrenia 195 (80.9%) 
        Paranoid Subtype 156 (80.0%) 
        Hebephrenic subtype 13 (6.7%) 
        Residual subtype 17 (8.7%) 
        Simple subtype 1 (0.5%) 
        Schizophreniform psychosis 8 (4.1%) 
SD – Standard Deviation 
 
 
Table 2 – Missing data in Paternal Age at Birth, Maternal Age at Birth and Birth Rank 
Variables   n admitted for statistics Missing data – n (%) 
Paternal Age at Birth 85 156 (64.7%) 
Maternal Age at Birth 109 132 (54.8%) 
Birth Rank 126 115 (47.7%) 
 
 
 
Table 3 – Frequency Statistics on Paternal Age at Birth, Maternal Age at Birth and 
Birth Rank 
Variables (n) Mean ± SD  Range (min – max)  Median  Mood  
Paternal Age at 
Birth (85) - years 
30.06 ± 6.79 15 – 42 30.00 28 
Maternal Age at 
Birth (109) – years 
28.01 ± 7.28 14 – 54 27.00 24 
Birth Rank (123) 2.18 ± 1.53 1 - 10 2.00 1 
SD – Standard Deviation; min – minimum value; max – maximum value 
 
 
Table 4 – Statistic Frequencies of Paternal Age Groups and Birth Rank Groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables  Number of Patients (n) Percentage of 
Patients (%) 
Paternal Age Group   
  <25 14 16.5 
  25 – 29 28 32.9 
  30 – 34 19 20.0 
  35 – 39 17 8.2 
  ≥ 40 7 2.9 
Birth Rank Group   
  1st  56 44.4 
  2nd  32 25.4 
  ≥ 3rd 38 30.2 
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scientific standards, such as the CONSORT / STROBE guidelines and the Uniform Requirements 
for Manuscripts Submitted to Biomedical Journals (ICJME).
The journal offers:
• Trusted peer review process
• Fast submission-to-publication time
• Open-access publication without author fees
• Multidisciplinary audience and global exposure
Contents
1. AIMS AND SCOPE 1
2. TYPES OF PAPERS 2
2.1. Original research articles 2
2.2. review articles and drug reviews 2
2.3. case repOrts and case snippets 2
2.4. viewpOints 3
2.5. letters tO the editOr 3
2.6. editOrials and guest editOrials 3
3. MANUSCRIPT SUBMISSION 3
3.1. cOver letter 3
3.2. Manuscript preparatiOn 3
3.3. suppOrting infOrMatiOn 5
3.4. subMissiOn checklist 6
4. OVERVIEW OF THE EDITORIAL PROCESS 6
4.1. appeal prOcess 6
Instructions for Authors
2
2. Types of papers
The International Journal of Clinical Neuroscience and Mental Health publishes scientific 
articles in the following categories:
• Original research articles. 
• Reviews.
• Drug reviews.
• Case reports.
• Case snippets.
• Viewpoints.
• Letters to the editor.
• Editorials and guest editorials.
2.1. Original research articles
The International Journal of Clinical Neurosciences and Mental Health welcomes original 
clinical research related with psychiatry, mental health, medical psychology, neurosurgery and 
neurology. 
Reports of randomized clinical trials should follow the CONSORT Guidelines and reports of 
observational studies should comply with STROBE Guidelines. 
Body text of an Original Research Article should have no more than 4000 words (word 
count excludes title page, abstract, acknowledgments, references and tables). A maximum of 6 
illustrations (figures or tables) are allowed. Supplementary online material may be submitted at 
the editor discretion.
2.2. Review articles and Drug Reviews
Review articles on CNS-related drugs, psychiatry, mental health, medical psychology, 
neurosurgery and neurology topics are welcome. Both invited and unsolicited submissions are 
accepted.
Manuscripts should be limited to a maximum of 4,500 words, excluding title page, abstract, 
acknowledgments, references and tables. 
2.3. Case reports and case snippets
Case Reports and Case Snippets should have no more than 750 and 500 words, respectively 
(word count excludes references); one figure or table can be included. 
Only highly meaningful Case Reports are accepted, including major educational content or 
major clinical findings. Case Snippets should describe a diagnosis or therapeutic challenge.
2.4. Viewpoints
Viewpoints should provide an expert opinion on important topics for medical research or 
practice, with possibility for covering social and policy aspects. This section encourages dialogue 
and debate on relevant issues with expert views based on evidence.
Viewpoints are limited to 1500 words (word count excludes references) and can include one 
figure or table.
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2.5. Letters to the Editor
Letters to the Editor should share views on published articles, any findings insufficient for a 
research article or present ideas of any subject in the scope of the journal.
Letters to the Editor have a maximum of 600 words (including references) and can include 
one figure or table.
2.6. Editorials and Guest Editorials
Authors are invited by the Editor-in-Chief to comment on specific topics and express their 
opinions. Editorials and Guest Editorials have a maximum of 1,000 words and can include one 
figure or table.
3. Manuscript Submission
These instructions advise on how the manuscript should be prepared and submitted. 
Manuscripts that do not comply with the guidelines will not be considered for review.
All manuscripts should be prepared in A4-size or US-letter size, in UK or US English. 
Manuscripts should be submitted in *.doc and *.pdf formats, in the appropriate section of the 
journal website: IJCNMH online submission.
3.1. Cover Letter
A cover letter should be submitted together with the manuscript, in *.doc or *.pdf format, 
addressed to the Editor-in-Chief. 
A template for the cover letter is available for download.
The cover letter should contain statements about originality of your publication, Ethics 
Committee approval and informed consent (if applicable), conflicts of interest and why in your 
opinion your manuscript should be published.
3.2. Manuscript Preparation
The manuscript must be divided in 2 files: the Title page (submitted in *.doc format and *.pdf 
formats) and the Manuscript body (submitted in *.doc and *.pdf formats). 
Title page
This should be submitted as a separate file from your manuscript (to assure anonymity in the 
peer review process) and should include:  
• Article title.
• Authors’ names, titles (e.g. MD, PhD, MSc, etc.) and institutional affiliations.
• Corresponding author: name, mailing address, telephone and fax numbers.
• Keywords (maximum of 10).
• A running head (up to 50 characters).
• Abstract word count (up to 250 words).
• Body text word count. 
• The number of figures and tables.
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Manuscript body:
The Manuscript body must be anonymous, not containing the names or affiliations of the 
authors. Manuscript body must be structured in the following order: title, abstract, body text, 
acknowledgements, references, tables, and figures captions/legends.
• The text must be formatted as follow:
• Arial fonts, size: 11 points.
• Single line spacing (see paragraph menu). 
• Aligned to the left (not justified). 
Showing continuous line numbers on the left border of the page. For MS Word you can add 
line numbers by going to: Page Layout -> Line Numbers -> select “Continuous”; for OpenOffice:  
Tools -> Line Numbering -> tick “Show numbering”.
Title  
A descriptive and scientifically accurate article title should be provided.
Abstract (250 words maximum)
An abstract should be prepared for Original Research Articles, Review Articles and Drug 
Reviews.
Should be structured and include: background/objective, material and methods, results, and 
conclusions. These sections should be separated by the respective headings. 
If the publication is associated with a registered clinical trial, the trial registration number 
should be referred at the end of the abstract.
Body text
Original research articles
Original research articles should be structured as follows:
Introduction: Should present the background for the investigation and justify its relevancy. 
Claims should be supported by appropriate references. Introduction should end by stating 
the objectives of the study.
Methods: Should allow the reproduction of results and therefore must provide enough 
detail. Appropriate subheadings can be included, if needed.
Results: Should include detailed descriptions of generated data. This section can be 
separated into subsections with concise self-explanatory subheadings.
Discussion and Conclusions: Should be brief but comprehensive and well argued, 
summarise and discuss the main findings, their clinical relevance, the strengths and 
limitations of the study, future perspectives with suggestion of experiments to be addressed 
in the future.
Review articles and Drug Reviews
These types of articles should be organized in sections and subsections.
Acknowledgements
This section should name everyone who has contributed to the work but does not qualify as 
an author. People mentioned in this section must be informed and only upon consent should 
their names be included along with their contributions. Financial support (with grant number, if 
applicable) should also be stated here.
Any conflict of interests should be declared. If authors have no declaration it should be 
written: “The authors declare no conflict of interests”.
References
References citation in the text should be numbered sequentially along the text, within 
brackets. 
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The use of a reference management tool (such as Endnote or Reference Manager) is 
recommended. References must be formatted in Vancouver style. 
Only published or accepted for publication material can be referenced. Personal 
communications can be included in the text but not in the references list. 
Tables
Tables should be smaller than a page, without picture elements or text boxes. Tables should 
have a concise but descriptive title and should be numbered in Arabic numerals. Table footnotes 
should explain any abbreviations or symbols that should be indicated by superscript lower-case 
letters on the body table.
Figures
Figures should have a concise but descriptive title and should be numbered in Arabic 
numerals. If the article is accepted for publication, the authors may be asked to submit higher 
resolution figures. Copyright pictures shall not be published unless you submit a written consent 
from the copyright holder to allow publishing.
Each figure file shall not be larger than 30MB. 
Figures should be tested and printed on a personal printer prior submission. The printed 
image, resized to the intended dimensions, is almost a replication of how the picture will look 
online. It shall be clearly perceived, non-pixelated nor grainy. Only flattened versions of layered 
images are allowed. Each figure can only have a 2-point white space border, thus cropping is 
strongly advised. For text within figures, Arial fonts between 8 to 11 points should be used and 
must be readable. When symbols are used, the font information should be embedded.
Photographs should be submitted as *.tif or *.eps at high-resolution (300 dpi or more). 
Graphics should be submitted in *.eps format. MS Office graphics are also acceptable.
All figures, tables and graphics should have white background and not transparent.
Lines, rules and strokes should be between 0.5-1.5 points for reproducibility purposes.
3.3. Supporting Information
Code of Experimental Practice and Ethics
The minimal ethics requirements are those recommended by the Code of Ethics of the World 
Medical Association (Declaration of Helsinki). Authors should provide information regarding 
ethics on research participants, patient informed consent, data privacy as well as competing 
interests. If the authors have submitted a related manuscript elsewhere should disclose this 
information prior submission. 
Nomenclature
All units should be in International System (SI). Drugs should be designated by their 
International Non-Proprietary Name (INN).
3.4. Submission Checklist
Please ensure you have addressed the following issues prior submission:
• Details for competing interests.
•  Details for financial disclosure.
•  Details for authors contribution.
•  Participants informed consent statement.
•  Contributor copyright authorization of figures included in the manuscript, not produced 
by the authors and subjected to copyright.
•  Authorship, affiliations and email addresses are correct.
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•  Cover letter addressed to the Editor-in-Chief.
•  Identification of potential reviewers and their email addresses (to be introduced at the 
online submission platform).
•  Manuscript, figure and tables comply with the author guidelines, including the correct 
format, SI units and standard nomenclature.
•  Separated files for Title page (*.doc and *.pdf) and Manuscript body (*.doc and *.pdf)—4 
in total.
•  Manuscript body does not contain the names or affiliations of the authors.
If you have any questions, please contact ijcnmh@arc-publishing.org
4. Overview of the Editorial Process
The International Journal of Clinical Neurosciences and Mental Health aims to provide an 
efficient and constructive view of the manuscripts submitted to achieve a high quality level of 
publications. The editorial board is constituted by expert leaders in several areas of medicine 
particularly in Clinical Neuroscience and Mental Health.  
Once submitted, the manuscript is assigned to an editor which evaluates and decides whether 
the manuscript is accepted for peer-review. At this initial phase, the editor evaluates if the 
manuscript fulfils the scope of the journal according to the content and minimum quality 
standards.  For peer-review, one or two additional expert field editors will comment on the 
manuscript and decide on whether it is accepted for publishing with minor corrections or not 
accepted for publishing. The editor may ask authors to resubmit after major revision. Decision 
is based on technical and scientific merits of the work. Reviewers can be asked to be disclosed 
or stay anonymous. Authors can exclude specific editors or reviewers from the process, upon 
submission, a rational should be provided.
Upon evaluation, an email is sent to the corresponding author with the decision. If accepted, 
the manuscript enters the production process. It takes approximately 6-7 weeks for the 
manuscript to be published.
4.1. Appeal Process
The editors will respond to appeals from authors which manuscripts were rejected. Their 
interests should be sent to the Editor. 
Two directions can be followed: 
• If the Editor does not accept the appeal, further right to appeal is denied.
• If the Editor accepts the appeal, a further review will be asked. After the new review, the 
editor can reject or accept the appeal. If rejected, nothing else can be done, if accepted the 
author is able to resubmit the manuscript.
The reasons for not accepting a manuscript for consideration can be:
•  The manuscript does not follow the scope of the journal.
•  The manuscript has potential interest but there are methodological concerns after peer-re-
view or editorial examination.


